Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
Sarepta Therapeutics(SRPT) stock is priced at $21.92, giving the company a market capitalization of 2.32B. It carries a P/E multiple of -2.58.
On 2026-04-01, Sarepta Therapeutics(SRPT) stock traded between a low of $21.65 and a high of $22.65. Shares are currently priced at $21.92, which is +1.3% above the low and -3.2% below the high.
Sarepta Therapeutics(SRPT) shares are trading with a volume of 2.07M, against a daily average of 4.71M.
During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $65.69 at its peak.
During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $65.69 at its peak.
SRPT News
Earlier this week, Sarepta Therapeutics reported the first human data from its SRP-1001 and SRP-1003 siRNA programs in FSHD1 and DM1, showing dose-dependent mus...
Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental siRNA therapies, which were acquir...
Deutsche Bank raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive pr...
Analyst ratings
46%
of 26 ratingsMore SRPT News
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bearish stance on SRPT stock, giving a Sell rating yesterday. Mitchell Kapoor has given his Sell r...
Citi analyst Yigal Nochomovitz has maintained their bearish stance on SRPT stock, giving a Sell rating on March 19. Yigal Nochomovitz has given his Sell rating...
Citi analyst Yigal Nochomovitz raised the firm’s price target on Sarepta (SRPT) to $13 from $9 and keeps a Sell rating on the shares. The firm says yesterday’s...
U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49, the S&P 500 gaining 0.5% to 6,591.90 and the Nasdaq advanci...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.